Galvin Gaustad & Stein’s Vertex Pharmaceuticals VRTX Stock Holding History

Galvin Gaustad & Stein’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$11.5M	Sell	22,048 -7,712	-26%	-$3.95M	0.87%	42
2026 Q2	$14.8M	Sell	29,760 -5,473	-16%	-$2.43M	1.09%	31
2026 Q1	$15.7M	Buy	35,233 +924	+3%	+$431K	1.26%	27
2025 Q4	$15.6M	Buy	34,309 +1,167	+4%	+$503K	1.21%	32
2025 Q3	$13M	Buy	33,142 +10,252	+45%	+$4.28M	1.05%	43
2025 Q2	$10.2M	Buy	22,890 +1,529	+7%	+$705K	0.88%	49
2025 Q1	$10.4M	Sell	21,361 -367	-2%	-$171K	0.93%	48
2024 Q4	$8.75M	Sell	21,728 -233	-1%	-$108K	0.78%	52
2024 Q3	$10.2M	Sell	21,961 -14,724	-40%	-$7.07M	0.91%	45
2024 Q2	$17.2M	Buy	36,685 +9,280	+34%	+$4.03M	1.6%	27
2024 Q1	$11.5M	Buy	27,405 +6,358	+30%	+$2.69M	1.05%	41
2023 Q4	$8.56M	Buy	+21,047	New	+$7.78M	0.8%	46

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $39.3B AUM 31.81% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Galvin Gaustad & Stein's VRTX Position: Q3 2026 in Review

Galvin Gaustad & Stein reduced its Vertex Pharmaceuticals (VRTX) stake by 26% in Q3 2026, selling an estimated $3.95M and leaving 22,048 shares worth $11.5M. The position accounts for 0.87% of the portfolio, ranked #42.

Galvin Gaustad & Stein first reported a position in VRTX in Q4 2023 and has held it in 12 quarters since. The position peaked at $17.2M in Q2 2024. 853 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Galvin Gaustad & Stein held 22,048 shares of Vertex Pharmaceuticals worth $11.5M as of Q3 2026.
Galvin Gaustad & Stein sold 7,712 Vertex Pharmaceuticals shares in Q3 2026, an estimated $3.95M.
Vertex Pharmaceuticals made up 0.87% of Galvin Gaustad & Stein's portfolio in Q3 2026, its #42 holding.
Galvin Gaustad & Stein first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
Galvin Gaustad & Stein's Vertex Pharmaceuticals position peaked at $17.2M in Q2 2024.
853 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Galvin Gaustad & Stein's 13F filing for Q3 2026, filed 8 Oct 2026.